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Attention-Deficit/Hyperactivity Disorder Following up
to Five Years of Treatment
Thomas J. Spencer, M.D.,1 Christopher J. Kratochvil, M.D.,2 R. Bart Sangal, M.D.,3
Keith E. Saylor, Ph.D.,4 Charles E. Bailey, M.D.,5 David W. Dunn, M.D.,6
Daniel A. Geller, M.B.B.S.,1 Charles D. Casat, M.D.,7 Robert S. Lipetz, D.O.,8
Rakesh Jain, M.D.,9 Jeffrey H. Newcorn, M.D.,10 Dustin D. Ruff, Ph.D.,11
Peter D. Feldman, Ph.D.,11 Amanda J. Furr, B.Sc.,6 and Albert J. Allen, M.D., Ph.D.11
ABSTRACT
Objective: To examine the effects on growth of long-term pharmacological treatment for at-
tention-deficit/hyperactivity disorder (ADHD), we present findings from an ongoing 5-year
study of the efficacy and safety of treatment with atomoxetine.
Methods: North American patients, 6–17 years old at study entry (N 5 1,312) and with Di-
agnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) ADHD, were stud-
ied under open-label atomoxetine treatment. Sixty-one were studied up to 5 years.
Results: After 1 month’s treatment, patients weighed less than expected from their starting
percentiles relative to population norms, with a maximum shortfall at 15 months and a return
to expected weight by 36 months. Patients were slightly shorter than expected after 12 months,
reaching a maximum shortfall at 18 months and returning to expected height by 24 months.
Patients in the top quartile for body mass index (BMI) or weight at baseline, and those in the
third quartile for height, showed 5-year decreases from expected values. Those below median
height at baseline showed increases relative to expected values.
Conclusions: These interim results indicate that continuous atomoxetine treatment for up
to 5 years has little or no long-term effect on juvenile growth and final stature for most pa-
tients, although persistent decreases from expected may occur in some patients who are larger
than average before treatment.
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INTRODUCTION
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER(ADHD) is one of the most common psy-
chiatric disorders in childhood, with an inci-
dence rate estimated at between 3% and 7%
(American Psychiatric Association 2000) in the
United States and similar rates found in other
regions of the world (Wang et al. 1993; Andres
Carrasco et al. 1995). In many patients, the dis-
order persists through adolescence and into
adulthood, requiring chronic treatment over
many years. Pharmacotherapy for ADHD has
relied for several decades on the psychostimu-
lants, particularly dextroamphetamine and
methylphenidate (MPH), but the range of
choices of medication has been considerably
expanded with the introduction of a nonstim-
ulant treatment, atomoxetine.
Studies conducted with both the psychos-
timulants and atomoxetine indicate that, at
least acutely, treatments for ADHD among
children and adolescents are associated with
significant suppression of growth in height and
weight (Safer et al. 1972; Michelson et al. 2001;
Sund and Zeiner 2002; MTA Cooperative
Group 2004; Spencer et al. 2005). However, few
studies have been carried out past the 2-year
time point, and the long-term effects on growth
of treatment for ADHD are still unclear. To ad-
dress this gap, we sought to examine the effects
of continuous atomoxetine treatment on height
and weight among children and adolescents
with ADHD over a span of up to 5 years, test-
ing the hypothesis that suppression of growth
in height and weight is a temporary phenom-
enon. The 2-year interim results have been pub-
lished previously (Spencer et al. 2005).
METHODS
Patient sample and study design
Recently, we analyzed the first set of 5-year
data from an ongoing 5-year longitudinal study
of the efficacy, safety, and tolerability of long-
term treatment with atomoxetine. The data set
includes all patients from previous Lilly clini-
cal trials of atomoxetine (13 studies: 6 placebo-
controlled, 7 open-label) who entered open-la-
bel atomoxetine treatment. This report presents
the data on patients’ weight, height, and body
mass index (BMI). Patients were children and
adolescents 6–17 years of age at the time of ini-
tial study enrollment, either male or female,
weighing at least 20 kg at baseline, and had
been diagnosed with ADHD, as defined in the
Diagnostic and Statistical Manual of Mental Dis-
orders, 4th edition (DSM-IV) (American Psy-
chiatric Association 1994), and confirmed with
the Schedule for Affective Disorders and Schiz-
ophrenia for School-age Children, Present and
Lifetime Version (K-SADS-PL; Kaufman et al.
1996). The drug development program allowed
patients who entered and completed a short-
term study the option of continuing treatment
in an extension study for a total exposure of up
to 5 years. Pre-extension trials ranged from 6
to 96 weeks in duration and used similar dose
ranges, with a starting dose of 0.5 mg/kg per
day, a target dose of 1.2 mg/kg per day, and a
maximum dose of up to 1.8 mg/kg per day in
most studies. Atomoxetine was administered
either once daily (3 studies) or as a divided
twice-daily dose (10 studies). Dosing during
the extension phase represented a continuation
of the treatment received during the acute
phase. If at any time a patient or investigator
felt that the patient was not obtaining sufficient
clinical benefit from treatment, participation
could be terminated.
In addition to the DSM-IV and K-SADS-PL
diagnostic entry criteria, initial criteria required
symptom severity to be at least 1.5 standard de-
viations (SD) above age and sex norms in 6 of
the 13 studies, and at least 1.0 SD above norms
in three of the studies, as assessed with the At-
tention-Deficit/Hyperactivity Disorder Rating
Scale-IV–Parent Version: Investigator Admin-
istered and Scored (ADHDRS-IV-Parent:Inv;
DuPaul et al. 1998; Faries et al. 2001). Patients
of any diagnostic subtype of ADHD were eli-
gible to participate. Exclusion criteria included
serious medical illness, mental retardation, ab-
normal baseline laboratory values, abnormal
baseline electrocardiograms, organic brain dis-
orders, a history of psychosis or bipolar disor-
der, alcohol or drug abuse within the past 3
months, and ongoing use of psychoactive med-
ication other than the study drug. Patients were
recruited by referral and by advertisement. The
studies were approved at each site by an Insti-
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tutional Review Board and were conducted in
accordance with the ethical standards of the
1975 Declaration of Helsinki, as revised in 2000
(World Medical Association 2000). Parents and
guardians signed consent forms, and assent
was given by patients before enrollment.
Assessments and statistical methods
A portion of patients received only placebo
treatment during the pre-extension treatment
period and were therefore exposed to atomoxe-
tine for the first time during the extension phase.
Accordingly, time zero for this analysis was de-
fined as the time at which a patient began re-
ceiving atomoxetine, whether in the pre-exten-
sion trial or in the extension phase. Weight was
measured at every visit in each trial, and height
was measured at the initial and final study vis-
its of the initial trial and at regular intervals not
to exceed 6 months during the extension phase.
Mean observed values and changes from base-
line of weight, height, and BMI were obtained
and expressed as a percentile and correspond-
ing z-score relative to population normative val-
ues for age and sex using the most current norms
from the National Center for Health Statistics
(NCHS) (Kuczmarski et al. 2000). Significance of
changes from baseline was assessed with Stu-
dent’s t-test and Wilcoxon’s signed rank test. Ex-
treme cases of difference from expected weight
or height were identified from patients’ base-
line-to-end point change z-scores, with extreme
cases identified by a change z-score below 21.96
or above 11.96, a threshold equivalent to the
limits of a two-tailed 95% confidence interval.
Longitudinal models such as the mixed-model
repeated measures analysis of variance were
used to assess changes over time. Dose effects
were examined using a regression model for
change in weight, height, or BMI z-score versus
modal dose. Categorical data were assessed
with Fisher’s exact test. All tests were conducted
using a two-sided significance level of 0.05.
RESULTS
Patient sample
A total of 1,312 patients entered the long-
term study. As indicated in Table 1, the major-
ity (76.5%) were boys, with a mean age at first
exposure to atomoxetine of 11.0 years (SD 5
2.5). Most (82.6%) were of Caucasian origin.
The most prevalent diagnostic category among
the 1,257 patients providing data was ADHD
of the combined type (64.8%), while 28.2% were
predominantly inattentive and 2.9% were pre-
dominantly hyperactive–impulsive. The final
mean dose of atomoxetine was 1.46 mg/kg per
day (SD 5 0.53). Sixty one patients to date have
reached the 5-year time point. This report will
focus on their longitudinal data set, as it is the
most complete. Demographics and baseline
characteristics for the 5-year subsample were
not appreciably different from those of the
overall study sample (Table 1), although pro-
portionally fewer patients diagnosed with the
predominantly inattentive subtype of ADHD
have reached the 5-year time point than have
entered the study initially. To date, 384 patients
(29.3%) remain enrolled in the study, having
not yet reached the 5-year time point. Another
926 (70.6%) have discontinued. The most fre-
quent reason for discontinuation to date has
been Personal Conflict/Other (25.4%), fol-
lowed by Loss to Follow-up (16.5%). Lack of
Efficacy accounts for 16.3%, while Adverse
Event accounts for 5.3%. Of the latter, only 1
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TABLE 1. PATIENT DEMOGRAPHICS AND
BASELINE CHARACTERISTICS
All patients 5-year patients
Characteristic (N 5 1,312) (N 5 61)
Sex, n (%)
Female 308 (23.5) 13 (21.3)
Male 1,004 (76.5) 48 (78.7)
Racial origin, n (%)
African American 95 (7.2) 3 (4.9)
Caucasian 1,084 (82.6) 53 (86.9)
East Asian 9 (0.7) 0 (0.0)
Hispanic 75 (5.7) 3 (4.9)
Other 49 (3.7) 2 (3.3)
Age at entry, years
Mean (SD) 11.0 (2.5) 10.2 (1.7)
Range 6.1–18.0 6.2–13.4
ADHD Subtype, n (%)
Combined 849 (64.8) 51 (83.6)
Hyperactive/Impulsive 38 (2.9) 1 (1.6)
Inattentive 370 (28.2) 9 (14.8)
Prev. Stim. Exp., n (%) 881 (67.8) 39 (63.9)
SD 5 Standard deviation; ADHD 5 attention-deficit/
hyperactivity disorder; Prev. Stim. Exp. 5 previous 
exposure to stimulants.
patient (0.1%) cited weight loss and 2 (0.2%)
cited decreased appetite as the adverse event
leading to discontinuation.
Weight results
At baseline, the observed-case mean weight
for the subsample of patients who have stayed
in the study and to date have reached 5 years of
therapy was 40.2 kg (SD 5 13.0), or 88.4 lb (SD 5
28.6), corresponding to a mean weight percentile
of 67.8 (Table 2), well above the NCHS median.
After 1 month of treatment, a significant decre-
ment was seen relative to the expected weight
(Fig. 1A), with patients falling to the 66.2 per-
centile (observed-case mean change from base-
line: 21.6 percentage points, SD 5 3.5, n 5 61,
p , 0.001). A maximum decrement from ex-
pected was reached at the 15th month of treat-
ment, with patients falling to the 57.9 percentile
(mean change: 29.9 percentage points, SD 5
14.2, p , 0.001). By the 36th month, the weight
was no longer significantly different from ex-
pected, with patients’ weight having risen to the
65.4 percentile (mean change: 23.1 percentage
points, SD 5 19.9, p 5 0.12), and by the 5-year
time point, patients had slightly overshot their
starting weight percentile, although not signifi-
cantly so, rising to the 70.5 percentile (mean
change: 12.6 percentage points, SD 5 22.8, 
p 5 0.75). The last-observation-carried-forward
mean weight difference from expected at 5
years, based on the starting percentile and ex-
trapolating from the growth norms for age- and
sex-matched controls, rather than from the per-
centile alone, was an increase relative to base-
line of 11.1 kg (SD 5 12.7), or 2.4 lb (SD 5 27.9),
representing a statistically nonsignificant in-
crease from the starting percentile of 1.1 points
(SD 5 22.4, p 5 0.70). No extreme cases of a
shortfall from predicted weight were found, and
one case of extreme gain was seen, with a pa-
tient starting the study with a height z-score of
20.61, equivalent to a percentile score of 26.9,
and completing with a z-score of 12.10, equiv-
alent to a percentile score of 93.1, an increase of
48.6 kg (106.9 lb) over the 5-years of the study,
rather than the 27.6 kg (60.7 lb) that was ex-
pected for this patient. Examination of the over-
all sample revealed no effects of modal dose on
changes in weight z-score (r2 , 0.001, p 5 0.85).
When patients who had reached the 5-year
time point were stratified on the basis of their
starting weight quartile, a pattern of differen-
tial growth in weight was observed over the 5-
year observation period (Table 3). The greatest
gains were seen in the patients who were light-
est at study entry. Patients with weight per-
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TABLE 2. CHANGES IN WEIGHT, HEIGHT, AND BODY MASS INDEX FROM BASELINE TO THE FIVE-YEAR TIME POINT
5-Year
Baseline: time point: Change:
Measure Value mean (SD) mean (SD) mean (SD) p value
Weight Actual (kg) 40.2 (13.0) 70.0 (20.0) 129.8 (13.3) ,0.001
(n 5 61) Predicted (kg) — 68.9 (17.1) 128.7 (7.6) ,0.001
Actual (lb) 88.4 (28.6) 153.9 (44.0) 166.5 (29.3) .—
Predicted (lb) — 151.5 (37.7) 163.1 (16.8) .—
z-scorea 0.72 (1.07) 0.77 (1.09) 10.05 (0.79) 0.62
Percentile 67.8 (28.1) 68.9 (27.4) 11.1 (22.4) 0.70
Height Actual (cm) 139.9 (11.7) 170.0 (9.6) 130.1 (8.2) ,0.001
(n 5 53) Predicted (cm) — 169.7 (9.3) 129.8 (6.9) ,0.001
Actual (in) 55.1 (4.6) 66.9 (3.8) 111.9 (3.2) .—
Predicted (in) — 66.8 (3.6) 111.7 (2.7) .—
z-scorea 0.23 (1.00) 0.27 (1.01) 10.04 (0.75) 0.71
Percentile 55.7 (28.9) 57.9 (29.6) 12.1 (23.6) 0.52
BMI Actual 19.5 (3.8) 24.1 (5.6) 14.5 (3.5) ,0.001
(n 5 52) Predicted — 24.0 (5.0) 14.4 (1.6) ,0.001
z-scorea 0.73 (1.01) 0.70 (1.09) 20.03 (0.83) 0.82
Percentile 70.3 (25.8) 68.1 (28.4) 22.2 (24.1) 0.52
SD 5 Standard deviation; BMI 5 body mass index; kg 5 kilogram; lb 5 pound; cm 5 centimeter; in 5 inch.
az-Scores are standard scores that indicate how far, and in what direction, an item deviates from its distribution’s
mean, expressed in units of its distribution’s standard deviation.
centiles that fell into successively higher quar-
tiles at baseline showed successively smaller in-
creases in weight percentile, with the heaviest
group at baseline in fact showing a significant
decrease in weight percentile at the 5-year time
point.
Height results
Observed-case mean height at baseline for
the patients to date who have reached the 5-
year time point was 139.9 cm (SD 5 11.7), or 4
feet 7 inches (SD 5 4.6 inches), corresponding
to a mean height percentile of 55.7 (Table 2),
slightly above the NCHS median. Twelve
months after initiation, a significant decrement
from expected height was apparent, with pa-
tients’ mean height percentiles falling to the
52.0 percentile (mean change from baseline:
23.4 percentage points, SD 5 10.8, n 5 45, p 5
0.022). A maximum decrement from expected
height was reached by the 18-month time point
(Fig. 1B), with patients’ mean height falling to
the 49.0 percentile (mean change: 26.6 per-
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TABLE 3. CHANGES IN WEIGHT, HEIGHT, AND BODY MASS INDEX PERCENTILE
FROM BASELINE TO THE FIVE-YEAR TIME POINT, BY BASELINE QUARTILE
Baseline 5-Year p value
percentile Baseline: time point: Change: for group
Measure range n mean (SD) mean (SD) mean (SD) differencesa
Weight percentile 0 to 25th 5 15.7 (6.6) 39.6 (30.4) 123.8 (28.5) 0.14
25th to 50th 17 41.0 (7.2) 51.5 (24.9) 110.4 (25.7) 0.11
50th to 75th 8 62.7 (8.4) 65.9 (22.3) 13.2 (16.9) 0.61
75th to 100th 31 92.2 (7.2) 84.0 (19.5) 28.2 (15.8) 0.007
Height percentile 0 to 25th 11 16.0 (7.3) 30.2 (24.7) 114.1 (20.8) 0.048
25th to 50th 13 38.0 (6.0) 54.3 (25.7) 116.3 (22.9) 0.025
50th to 75th 8 59.3 (8.2) 43.3 (15.1) 215.9 (10.7) 0.004
75th to 100th 21 86.2 (6.6) 80.1 (21.6) 26.1 (21.7) 0.21
BMI percentile 0 to 25th 3 9.9 (12.9) 47.6 (44.2) 137.7 (33.5) 0.19
25th to 50th 11 42.7 (6.4) 47.6 (24.2) 15.0 (22.8) 0.49
50th to 75th 11 63.3 (6.0) 57.9 (28.6) 25.5 (27.4) 0.52
75th to 100th 27 91.1 (7.0) 83.0 (19.9) 28.2 (17.9) 0.026
SD 5 Standard deviation; BMI 5 body mass index.
ap values were derived from paired t-tests to assess within-group differences.
A B
FIG. 1. Mean percentile weight (A) and height (B) as a function of time of exposure to atomoxetine. Data include
all patients with a baseline measurement and a measurement at or after the 5-year time point. The dashed lines in-
dicate the baseline percentiles. The number of patients at each data point varies between 53 and 61 for the weight
curve, and between 51 and 53 for the height curve, due to the fact that not all patients provided both sets of data at
each time point. ap , 0.05, relative to baseline percentile; bp , 0.001, relative to baseline percentile.
centage points, SD 5 13.1, p , 0.001), but by 24
months, mean percentile was no longer signif-
icantly different from expected, with patients’
mean height rising slightly to the 49.7 per-
centile (mean change: 23.9 percentage points,
SD 5 15.2, p 5 0.09). By the 54th month, pa-
tients slightly overshot their starting percentile
(mean change: 10.2 percentage points, SD 5
24.5, p 5 0.99), and at 5 years, patients were at
the 58.8 percentile (mean change: 12.7 per-
centage points, SD 5 23.9, p 5 0.48). The last-
observation-carried-forward mean height dif-
ference from expected at 5 years, extrapolating
from the growth norms for age- and sex-
matched controls, was 10.3 cm (SD 5 5.3), or
10.1 inches (SD 5 2.1 inches), a statistically
nonsignificant increase in percentile of 2.1
points (SD 5 23.6, p 5 0.517). One extreme case
of a decrement from predicted height was
found, with a patient starting the study with a
height z-score of 11.10, equivalent to a per-
centile score of 86.4, and completing with a z-
score of 22.37, equivalent to a percentile score
of 10.30, in effect, a growth of just 4.5 cm (1.8
inches) over the 5-years of the study, rather
than the 19.8 cm (7.8 inches) that was expected
for this patient. No cases of extreme gain in
height were seen. Examination of the overall
sample revealed no effects of modal dose on
changes in height z-score (r2 , 0.001, p 5 0.89).
Stratified on the basis of starting height quar-
tiles, patients reaching the 5-year time point
again showed differential growth patterns over
the 5-year observation period (Table 3). While
not exactly a graded pattern as for weight per-
centiles, patients in the lower two quartiles
showed significantly greater increases in height
relative to age and sex norms, with the short-
est patients at baseline demonstrating the
largest mean increase in height percentile. Pa-
tients in the upper quartiles, by contrast,
showed decreases in height percentile from
baseline, with the greatest decrease, reaching
statistical significance, occurring in the third
quartile. These patients, on average, arrived at
the 5-year time point with a height that was in
fact below the median. The decrease in the
highest baseline quartile was considerably less,
and the difference from baseline did not
achieve statistical significance.
BMI results
Observed-case mean BMI at baseline for pa-
tients reaching the 5-year time point (Table 2)
was 19.5 (SD 5 3.8), corresponding to a mean
BMI percentile of 70.3, nowhere near levels of
obesity, but again well above the norm for age-
and sex-matched peers. By the 5-year time
point, patients’ mean BMI percentile had fallen
slightly to 68.1 (SD 5 28.4), a 2.2-point decrease
from baseline (p 5 0.52). No extreme cases of a
shortfall from predicted BMI were found, and
one case of extreme gain was seen, with a pa-
tient starting the study with a BMI z-score of
20.68, equivalent to a percentile score of 24.8,
and completing with a z-score of 12.05, equiv-
alent to a percentile score of 91.5, an increase
in BMI from 15.2 at baseline to 24.7 at the 5-
year time point. This case involved a different
patient from those involved in the cases of ex-
treme gain in weight or extreme decrement in
height. Examination of the overall sample re-
vealed no effects of modal dose on changes in
BMI z-score (r2 , 0.001, p 5 0.94). Stratified by
starting BMI quartile, patients again showed a
graded pattern of growth over the 5-year ob-
servation period (Table 3), but the only statis-
tically significant change in percentile occurred
in the patients with highest BMIs at baseline,
possibly reflecting the decrease in weight per-
centile among patients in the top quartile for
weight at baseline.
DISCUSSION
These results represent the largest data set to
date of patients studied for the effects of ADHD
treatment on growth over such an extended pe-
riod. The findings indicate that there is a small,
temporary decrement in growth rate associated
with chronic use of atomoxetine in developing
children and adolescents. The decrement of
growth in weight was noticeable by the first
postbaseline time point after 1 month of con-
tinuous treatment, followed nearly a year later
by a very brief decrement of growth in height.
Mean actual height returned to expected val-
ues by the end of the second year of treatment,
and mean actual weight returned by the end of
the third year, indicating that any effects on de-
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velopment overall were neither persistent nor
irrecoverable. The timing of the decrement in
growth rates suggests that one possible mech-
anism is an effect of the medication on appetite.
Nausea and stomach pain are frequently re-
ported during the early stages of treatment
with atomoxetine (Kratochvil et al. 2001;
Spencer et al. 2002), and it is possible that this
could have influenced patients’ desire to eat, as
has been seen in studies involving MPH
(Kramer et al. 2000). Alternatively, the putative
loss of appetite could have been due to a
temporary perturbation of the central nora-
drenergic systems involved in hunger or sati-
ety (Wellman 2000), similar to the dopamin-
ergic system-mediated appetite suppression
associated with the use of the stimulants (Freed
and Mizel 1952; Poindexter 1960). Alterna-
tively, this treatment could have directly af-
fected neuroendocrine systems involved with
growth mechanisms, also known to be under
catecholaminergic control, although this possi-
bility is unlikely, given that disturbances of
hormonal levels have not been seen in previ-
ous studies with atomoxetine (Kratochvil et al.
2001; Spencer et al. 2002).
The reversibility of the growth deficits seen in
this study is reassuring, because it indicates that
atomoxetine is unlikely to have a permanent ef-
fect on growth and final stature. These findings
extend those in past studies with the compound.
This is particularly salient, because younger chil-
dren may be the most affected by any potential
growth-suppressant effects of ADHD treatment
(Faraone et al. 2005a; Spencer et al. 1996; Zachor
et al. 2006), although this has not been a consis-
tent finding (Schertz et al. 1996; Sund and Zeiner
2002). Kratochvil and colleagues (Kratochvil et
al. 2006) conducted a meta-analysis of 13 stud-
ies involving atomoxetine and showed that, in
young children (6–7-years old), the effects of ato-
moxetine on growth appeared to begin to re-
verse but were nevertheless still quite apparent
at the 2-year time point. By contrast, an analy-
sis by Wilens et al. (Wilens et al. 2006) of ado-
lescents with ADHD showed a complete rever-
sal of any effect of atomoxetine on mean height
and weight by 2 years of treatment.
Underscoring these results is the finding that
children are more susceptible than adolescents
to treatment-emergent appetite suppression
and other gastrointestinal effects (Wilens et al.
2006). This supports the notion that the effects
of treatment on growth are felt more acutely 
in younger patients. Charach and associates
(Charach et al. 2006) examined the effects of
psychostimulants on growth over a period of
up to 5 years in a small group of preadolescent
children. Their results suggest that a “small but
distinct risk” of a persistent decrement in
growth rate occurs with long-term use of stim-
ulants, and that such risk increases with the
dose, particularly above recommended doses
(.2.0 mg/kg per day MPH-equivalents). De-
spite such findings, however, the persistence of
growth deficits beyond the second or third year
of treatment with psychostimulants appears
unlikely, as the predominance of evidence in-
dicates that growth deficits tend to attenuate
by the end of the first or second year, with
growth rates returning toward expected levels
by the second or third year (Satterfield et al.
1979; Poulton and Cowell 2003; Faraone et al.
2005a; Spencer et al. 2006; Zachor et al. 2006).
When patients in the present study were
classified according the quartile of their start-
ing weight, height, or BMI percentiles (relative
to norms), differences in patterns of growth
were seen, whereby the children who were
smallest at baseline showed the greatest in-
creases in growth above expected, while those
who were largest at baseline showed the great-
est decreases relative to expected. This pattern
was not uniform, however, for while patients
below the median for weight at baseline
showed considerable increases above their
predicted weight percentile at the 5-year time
point, the differences from predicted in fact
did not achieve statistical significance. More-
over, whereas patients below the median for
height at baseline showed significant increases
in height percentile over prediction, and those
in the third quartile (50 to 75 percentiles) per-
sistently showed a significantly lower height
percentile from predicted, those in the top
quartile showed a height percentile at 5 years
that was not significantly different from pre-
dicted.
It is unclear whether these differential pat-
terns of changes in growth reflect a true size-
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based difference of treatment on growth rates,
whether children were simply “normalizing”
in body size over time independently of treat-
ment, or if this merely represents a form of sta-
tistical “regression to the mean.” A “normaliz-
ing” effect is an unlikely cause, because a
decrement was seen in the growth in height, as
well as in weight, while a simple regression to
the mean is also questionable, because the pat-
terns of overshoot and undershoot from ex-
pected growth across size classes were not uni-
form, as, for example, the height decrement in
the third quartile (50th to 75th percentile) was
greater than the nonsignificant decrement in
the top quartile. Alternatively, patients who
were smaller at baseline may represent chil-
dren with a later onset of puberty, and their
greater growth during treatment may simply
reflect a “catching up” in size with their peers.
Unfortunately, Tanner-stage data were not cap-
tured during these studies, so the current re-
sults do not address whether the patient sam-
ple showed a change in the tempo of puberty
relative to norms or whether the treatment had
an effect on maturation. The latter appears un-
likely, however, as a previous atomoxetine
study (Michelson et al. 2004) that included an
assessment of Tanner stages has shown that the
treatment appears not to affect maturation or
its timing.
This putative differential size-based effect 
of treatment on growth is consistent with the
results from past studies of treatments for
ADHD. Studies involving the psychostimu-
lants (Schertz et al. 1996; Faraone et al. 2005a;
Zachor et al. 2006) have also revealed that chil-
dren who are largest at baseline show the
greatest growth deficits, whereas those who
are smallest show the least effect. A common
finding, and one that contradicts the stereo-
type of the underweight, hyperkinetic child
with ADHD, is that children with ADHD in
clinical trials tend to be heavier than expected
from norms at baseline (Sund and Zeiner 2002;
Holtkamp et al. 2004; Faraone et al. 2005b;
Spencer et al. 2006). In fact, one theory sug-
gests that there is a linkage between ADHD
and obesity through what has been referred to
as an “environmental oversampling disorder”
(Bazar et al. 2006), a phenomenon by which 
an individual is predisposed to taking in an
excess of environmentally supplied stimuli,
with ingestive behavior merely representing
one type of stimulus-seeking behavior. Other
analyses suggest that the prevalence of obesity
among children with ADHD may merely re-
flect that of the general population (Curtin 
et al. 2005). During long-term treatment for
ADHD, weight among the heavier children ap-
pears to “normalize,” and a decrease is seen
over time in the proportion of overweight chil-
dren. Nevertheless, deficits in weight, height,
and BMI did occur among patients in the
“lower quartiles as well, so considerable vigi-
lance is still warranted in monitoring patients’
tolerance to treatment with respect to growth
deficits.
One point of interest in any study of changes
in growth pattern during pharmacological
treatment is whether any such effects are asso-
ciated with the magnitude of the dose. In the
present study, we found no relation between
patients’ modal doses of atomoxetine and the
magnitude of the differences between their ex-
pected and actual growth. Similar findings have
also been obtained in most studies involving the
psychostimulants, because effects on growth
are typically seen over the entire range of doses
administered (Lisska and Rivkees 2003; Schertz
et al. 1996; Pliszka et al. 2006). This contrasts
with the findings by Charach et al. (Charach et
al. 2006), who found that only doses of psy-
chostimulant above the equivalent of 1.5 mg/kg
per day of MPH were associated with a sig-
nificant risk of a diminished growth rate for
weight, whereas doses above the equivalent of
2.5 mg/kg per day were associated with a sig-
nificant risk of a decreased growth rate for
height. It should be noted, however, that the lat-
ter dose is at the upper end of the recommended
maximum dose for stimulants (2.0–2.5 mg/kg
per day), whereas the doses of atomoxetine
used in the present study were generally within
the recommended range.
Because this was a long-term study, one of its
limitations was the difficulty of maintaining pa-
tients in the study long enough to reach the 5-
year time point. Rates of discontinuation due to
an adverse event (5.3%) or lack of efficacy
(16.3%) were notably low, but the overall dis-
continuation rate (70.6%) was high, as expected
from a study of this length. Consequently, the
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sample size at the 5-year time point is less than
optimal, making it more difficult to conduct sec-
ondary analyses of subgroups with sufficient
statistical power. Moreover, the data taken at the
5-year time point represent a somewhat skewed
sample, because patients who were able to re-
main in the study for that length of time may
not be representative of those who were not.
This may be a minor point, however, as the over-
whelming majority of discontinuations occurred
for reasons not related to tolerance or efficacy.
Also ameliorating this weakness to some extent
is the fact that this was a large study, with an
entering sample size of well over a thousand pa-
tients. Doses were well controlled and kept
within recommended guidelines, so that, while
the study sample may not represent a natural-
istic and numerically defined cohort as in the
only other 5-year drug growth study to date,
conducted by Charach et al. (Charach et al.
2006), the present study avoids many of the lim-
itations of that study, which was characterized
by incomplete descriptions of patient disposi-
tion and heterogeneous levels of exposure
within its defined dose ranges. Nevertheless,
another source of skewing arises from the na-
ture of the North American ADHD patient pop-
ulation itself, which the sample reflects in con-
sisting of a majority of males, Caucasians, and
patients of the combined diagnostic subtype.
Therefore, these findings may not generalize to
each ADHD patient, although the findings with
this sample should be still representative of the
overall U.S. patient population.
Due also to its long-term nature, this study
was conducted under nonrandomized, open-
label conditions, because it would have been
unethical to maintain a patient on placebo for
such a protracted period. This makes it diffi-
cult to discern whether observed changes or
differences from norms are due to the treat-
ment or to the condition itself. The previous
discussion of obesity illustrates the confusion
that can be generated from the reliance on stan-
dard growth curves in the absence of a control
for the untreated disease state. The situation is
further complicated by the recalibration that
such standard curves have undergone, such
that the median weight they now describe is
more prescriptive than descriptive in nature.
Although the average weight in the population
has been increasing over time, average height
has remained stable. To avoid contributing to
the trend of increasing obesity in the United
States, the standards committee that con-
structed the most recent norms decided to use
the population statistic for weight from earlier
studies with lower mean absolute values. As a
result, the average relative weight in the pop-
ulation today is expected to be greater than the
50th percentile described by the growth curves
currently used as the norm.
In summary, these findings show that use of
atomoxetine among 6- to 18-year-olds is asso-
ciated with a modest slowing of growth veloc-
ity over the initial 18 months, followed by a re-
turn to expected weights and heights by 2–3
years. Mean z-scores and percentiles for
weight, height, and BMI were not significantly
different from baseline from approximately the
3-year time point onward. However, analysis
by quartile showed that weight deficits per-
sisted to the 5-year time point among patients
who were heaviest at baseline, and patients in
the top quartile at baseline showed a signifi-
cant mean decrease in BMI. In contrast, patients
who were shortest at baseline showed a signif-
icant mean increase in height above expected.
These results suggest that, for most children
and adolescents with ADHD, atomoxetine
appears unlikely to have a persistent effect on
growth and final stature, although some
younger patients who are heavier or taller than
average may show persistent decreases from
expected weight or height over time.
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